Benitec Biopharma (BNTC) Fundamental Analysis: Revenue, Earnings & Valuation

8.43 / 10

Outperform

Fundamental score is 8.4/10, rated Outperform. Highlights include high interest coverage (35.1), strong revenue growth (operating revenue YoY 177%), and solid inventory turnover. Weak points are a high current‑liabilities ratio (78.5%) and low PB‑ROE, limiting upside.

Analysis Checks(8/10)

Revenue-MV

Value-0.11

Score3/3

Weight43.21%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.59%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-4.93%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value78.45

Score0/3

Weight-18.26%

1M Return-4.96%

PB-ROE

Value0.74

Score0/3

Weight14.55%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value0.01

Score2/3

Weight-1.53%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-5.01%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.24%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-4.73%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight75.86%

1M Return11.61%

Is BNTC undervalued or overvalued?

BNTC scores 8.43/10 on fundamentals and holds a Discounted valuation at present. Backed by its -14.62% ROE, 0.00% net margin, -8.46 P/E ratio, 1.99 P/B ratio, and -127.14% earnings growth, these metrics solidify its Outperform investment rating.